Two phase 3 trials reported a prolonged survival in the third‐line setting of colorectal cancer patients treated with regorafenib with the longest duration of treatment of 16 months. Herein, we reported a unique case of a patient refractory to conventional chemotherapy who showed a prolonged stable disease with regorafenib.
|Titolo:||Long‐term survival of an advanced colorectal cancer patient treated with Regorafenib: Case report and literature review|
|Data di pubblicazione:||2019|
|Appare nelle tipologie:||1.1 Articolo in rivista|